Education
About Us
Working with TipRanks
Follow Us
Greenwich Lifesciences, Inc. (GLSI)
NASDAQ:GLSI
GLSI Stock Chart & Stats
$9.28
-$0.46(-3.33%)
At close: 4:00 PM EST
$9.28
-$0.46(-3.33%)
Day’s Range― - ―
52-Week Range$7.78 - $34.10
Previous Close$13.65
Volume34.11K
Average Volume (3M)762.50K
Market Cap
$401.78M
Enterprise Value$407.26M
Total Cash (Recent Filing)$3.81M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.71
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.21
Shares Outstanding13,854,539
10 Day Avg. Volume419,736
30 Day Avg. Volume762,505
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)57.68
Price to Sales (P/S)0.00
P/FCF Ratio-20.11
Enterprise Value/Market Cap1.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-151.85K
Enterprise Value/Ebitda-20.87
Forecast
1Y Price Target
$47.50Price Target Upside411.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.36
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And Population ExpansionA substantial reduction in breast cancer recurrence in patients without a common HLA marker, with similar immune response and safety across trial arms, suggests GLSI-100 could be effective in a broader patient population and materially increase the addressable market.
Regulatory MilestoneFDA approval of a commercial GP2 lot lowers regulatory risk and supports advancement toward a Biologics License Application for GLSI-100.
Supply Readiness And Funding FlexibilityCommercial GP2 vials available for storage or direct use in trials improve launch readiness, while continued use of ATM financing provides a bridge to non-dilutive funding options such as strategic partnerships or debt and royalty financing.
Bears Say
Greenwich LifeSciences News
GLSI FAQ
What was Greenwich Lifesciences, Inc.’s price range in the past 12 months?
Greenwich Lifesciences, Inc. lowest stock price was $7.78 and its highest was $34.10 in the past 12 months.
What is Greenwich Lifesciences, Inc.’s market cap?
Greenwich Lifesciences, Inc.’s market cap is $401.78M.
When is Greenwich Lifesciences, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Greenwich Lifesciences, Inc.’s earnings last quarter?
Currently, no data Available
Is Greenwich Lifesciences, Inc. overvalued?
According to Wall Street analysts Greenwich Lifesciences, Inc.’s price is currently Undervalued.
Does Greenwich Lifesciences, Inc. pay dividends?
Greenwich Lifesciences, Inc. does not currently pay dividends.
What is Greenwich Lifesciences, Inc.’s EPS estimate?
Greenwich Lifesciences, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Greenwich Lifesciences, Inc. have?
Greenwich Lifesciences, Inc. has 13,854,539 shares outstanding.
What happened to Greenwich Lifesciences, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Greenwich Lifesciences, Inc.?
Currently, no hedge funds are holding shares in GLSI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Greenwich LifeSciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$47.50 (411.85% Upside)
$47.50 (411.85% Upside)
Blogger Sentiment
Bullish
GLSI Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $468.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 36.6%
Last 30 Days ▲ 36.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
132.18%
12-Months-Change
Fundamentals
Return on Equity
-543.43%
Trailing 12-Months
Asset Growth
-34.64%
Trailing 12-Months
Company Description
Greenwich Lifesciences, Inc.
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
GLSI Stock 12 Month Forecast
Average Price Target
$47.50
▲(411.85% Upside)
Technical Analysis
Ownership Overview
40.45% Insiders
3.01% Mutual Funds
0.02% Other Institutional Investors
53.02% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---